Nesiritide is not associated with the proarrhythmic effects of dobutamine in the treatment of decompensated CHF: The PRECEDENT study
Andrew J. Burger(Beth Israel Deaconess Medical Center), Jalal K. Ghali(Launchpad Central (United States)), Thierry H. LeJemtel(University of Maryland, Baltimore), Uri Elkayam(University of Southern California), Darlene P. Horton(Napo Pharmaceuticals (United States))
Cited by 16
Related Papers
Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
|American Heart Journal|2005|2.1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
|New England Journal of Medicine|2000|908
Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT study
|American Heart Journal|2002|323
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure
|Journal of the American College of Cardiology|1999|323